The effects of alendronate on the suppression of bone resorption and the promotion of cartilage formation in the human mosaicplasty donor site: A randomized, double-blind, placebo-controlled prospective study

2021 ◽  
Author(s):  
Yasuaki Nakagawa ◽  
Shogo Mukai ◽  
Koji Mori ◽  
Hiromitsu Yabumoto ◽  
Ryota Nakamura ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Prospective Study ◽  
Donor Site ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Cartilage Formation

scholarly journals Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption

1996 ◽  
Vol 42 (10) ◽  
pp. 1639-1644 ◽  
Author(s):  
M Bonde ◽  
C Fledelius ◽  
P Qvist ◽  
C Christiansen
Keyword(s):  
Bone Resorption ◽  
Postmenopausal Women ◽  
Type I Collagen ◽  
Premenopausal Women ◽  
Type I ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Analytical Recovery ◽  
Controlled Clinical Study ◽  
Different Doses

Abstract We present a coated-tube RIA that is useful for assessment of bone resorption. The assay uses a monoclonal antibody raised against a linear 8-amino-acid sequence (EKAHDGGR) derived from the C-telopeptides of type I collagen. Within-run and total CVs were 4.4% and 5.3-6.2%, respectively, at concentrations of 1-7 mg/L (n = 4-20). Analytical recovery was 98% +/- 8% and dilution 97% +/- 7%. Values obtained in a group of 36 premenopausal women were 227 +/- 89.6 mg/mol creatinine. In a group of 141 postmenopausal women, the values obtained were 429 +/- 225 mg/mol creatinine, a highly significant increase of 89% (P <0.001) over the premenopausal value. In a double-blind placebo-controlled clinical study of these postmenopausal women receiving five different doses of a bisphosphonate, a significant decrease of RIA-measured C-telopeptide values was seen in all bisphosphonate-treated groups, after just 3 months. Values in urine samples from postmenopausal women assayed with the RIA (gamma) and the CrossLaps(TM) ELISA (x) agreed well: slope = 0.98 (95% confidence interval, 0.94-1.01), intercept = 0.34 (0.25-0.43) mg/L, and Sylx = 0.93 mg/L (n = 678). We conclude that this RIA represents a valuable tool for assessing bone resorption.

The Effects of Clomipramine Hydrochloride in Cats With Psychogenic Alopecia: A Prospective Study

2006 ◽  
Vol 42 (5) ◽  
pp. 336-343 ◽  
Author(s):  
Petra A. Mertens ◽  
Sheila Torres ◽  
Carl Jessen
Keyword(s):  
Clinical Trial ◽  
Prospective Study ◽  
Treatment Duration ◽  
Drug Efficacy ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
A Prospective Study ◽  
To Receive ◽  
Insufficient Number

A double-blind, placebo-controlled clinical trial was conducted to determine the efficacy of clomipramine hydrochloride in cats with psychogenic alopecia. Twenty-five cats were randomly assigned to receive clomipramine hydrochloride (0.5 mg/kg orally q 24 hours) or placebo for 56 days. Eleven cats in each group completed the trial. The results of this study showed that clomipramine hydrochloride failed to demonstrate significant changes in the number of grooming bouts, hair regrowth, and the area of alopecia in cats with psychogenic alopecia when compared to a placebo. It was uncertain whether these results reflected a lack of drug efficacy, insufficient treatment duration, or an insufficient number of cases enrolled.

Intrathecal steroids to reduce pain after lumbar disc surgery: a double-blind, placebo-controlled prospective study

Pain ◽  
1995 ◽  
Vol 62 (3) ◽  
pp. 357-361 ◽  
Author(s):  
Johann J. Langmayr ◽  
Alois A. Obwegeser ◽  
Andreas B. Schwarz ◽  
Ilse Laimer ◽  
Hanno Ulmer ◽  
...  
Keyword(s):  
Prospective Study ◽  
Lumbar Disc ◽  
Lumbar Disc Surgery ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Disc Surgery

scholarly journals Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study

2014 ◽  
Vol 19 (6) ◽  
pp. 933-939 ◽  
Author(s):  
Yasuaki Nakagawa ◽  
Shogo Mukai ◽  
Shigeru Yamada ◽  
Masayuki Matsuoka ◽  
Eri Tarumi ◽  
...  
Keyword(s):  
Knee Osteoarthritis ◽  
Prospective Study ◽  
Short Term ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Short Term Effects

scholarly journals Lisinopril as a prophylactic agent for migraine: a randomised double blind placebo controlled cross over prospective study in Kashmir

2021 ◽  
Vol 8 (4) ◽  
pp. 536
Author(s):  
Irfan Yousuf Wani ◽  
Sheikh Saleem ◽  
Iqra Mehraj
Keyword(s):  
Prospective Study ◽  
Treatment Period ◽  
Severity Index ◽  
Double Blind ◽  
Once Daily ◽  
Double Blind Placebo ◽  
Prophylactic Agent ◽  
Headache Severity ◽  
Prophylactic Drug ◽  
Normotensive Subjects

Background: Migraine is one of the commonest neurological disorder seen by neurologists. Many different medications are available to be used as prophylactic agent. We conducted this study to determine the efficacy of Lisinopril as a prophylactic drug for migraine in our region.Methods: Our study is a randomised double blind, placebo controlled, cross over, prospective study. 60 patients were included in this study. Treatment period of 12 weeks with one 10 mg lisinopril tablet once daily for one week then two 10 mg lisinopril tablets once daily for 11 weeks, followed by a two week wash out period. Second treatment period of one placebo tablet once daily for one week and then two placebo tablets for 11 weeks. Thirty participants followed this schedule, and 30 received placebo followed by lisinopril. Primary end points were number of hours with headache, number of days with headache, number of days with migraine.Results: Statistical analysis of data from 41 patients that completed this study revealed that hours with headache, days with headache, days with migraine, and headache severity index were significantly reduced by 16%, 16% , 23% and 17% , respectively, with lisinopril as compared to placebo.Conclusions: This study favours lisinopril as an effective prophylactic drug for migraine. The adverse effects of lisinopril, though of significant frequency, have been mild to moderate in severity but were well tolerated by even normotensive subjects.

Sign in / Sign up

Export Citation Format

Share Document